{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,9,20]],"date-time":"2025-09-20T22:11:50Z","timestamp":1758406310584},"reference-count":26,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2017,12,22]],"date-time":"2017-12-22T00:00:00Z","timestamp":1513900800000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Med Oncol"],"published-print":{"date-parts":[[2018,1]]},"DOI":"10.1007\/s12032-017-1075-2","type":"journal-article","created":{"date-parts":[[2017,12,22]],"date-time":"2017-12-22T08:51:34Z","timestamp":1513932694000},"update-policy":"http:\/\/dx.doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["Chemotherapy and echocardiographic indices in patients with non-Hodgkin lymphoma: the ONCO-ECHO study"],"prefix":"10.1007","volume":"35","author":[{"given":"Katarzyna","family":"Mizia-Stec","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marek","family":"El\u017cbieciak","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maciej T.","family":"Wybraniec","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Monika","family":"R\u00f3\u017cewicz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Artur","family":"Bodys","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wojciech","family":"Braksator","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zbigniew","family":"G\u0105sior","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Piotr","family":"Go\u015bciniak","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tomasz","family":"Hryniewiecki","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jaros\u0142aw","family":"Kasprzak","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andrzej","family":"Wojtarowicz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Barbara","family":"Zdziarska","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Edyta","family":"P\u0142o\u0144ska-Go\u015bciniak","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2017,12,22]]},"reference":[{"key":"1075_CR1","doi-asserted-by":"crossref","first-page":"1374","DOI":"10.1016\/j.ejca.2012.12.027","volume":"49","author":"J Ferlay","year":"2013","unstructured":"Ferlay J, Steliarova-Foucher E, Lortet-Tieulent J, et al. Cancer incidence and mortality patterns in Europe: estimates for 40 countries in 2012. Eur J Cancer. 2013;49:1374\u2013403.","journal-title":"Eur J Cancer"},{"key":"1075_CR2","doi-asserted-by":"crossref","first-page":"2768","DOI":"10.1093\/eurheartj\/ehw211","volume":"37","author":"JL Zamorano","year":"2016","unstructured":"Zamorano JL, Lancellotti P, Mu\u00f1oz D, et al. Authors\/Task Force Members, ESC Committee for Practice Guidelines (CPG):2016 ESC Position Paper on cancer treatments and cardiovascular toxicity developed under the auspices of the ESC Committee for practice guidelines: the task force for cancer treatments and cardiovascular toxicity of the European Society of Cardiology (ESC). Eur Heart J. 2016;37:2768\u2013801.","journal-title":"Eur Heart J"},{"key":"1075_CR3","doi-asserted-by":"crossref","first-page":"620","DOI":"10.1038\/nrcardio.2015.133","volume":"12","author":"MS Ewer","year":"2015","unstructured":"Ewer MS, Ewer SM. Cardiotoxicity of anticancer treatments. Nat Rev Cardiol. 2015;12:620.","journal-title":"Nat Rev Cardiol."},{"key":"1075_CR4","doi-asserted-by":"crossref","first-page":"877","DOI":"10.1016\/j.jcmg.2012.11.017","volume":"6","author":"BC Drafts","year":"2013","unstructured":"Drafts BC, Twomley KM, D\u2019Agostino R Jr, et al. Low to moderate dose anthracycline-based chemotherapy is associated with early noninvasive imaging evidence of subclinical cardiovascular disease. JACC Cardiovasc Imaging. 2013;6:877\u201385.","journal-title":"JACC Cardiovasc Imaging."},{"key":"1075_CR5","doi-asserted-by":"crossref","first-page":"911","DOI":"10.1016\/j.echo.2014.07.012","volume":"27","author":"JC Plana","year":"2014","unstructured":"Plana JC, Galderisi M, Barac A, et al. Expert consensus for multimodality imaging evaluation of adult patients during and after cancer therapy: a report from the American Society of Echocardiography and the European Association of Cardiovascular Imaging. J Am Soc Echocardiogr. 2014;27:911\u201339.","journal-title":"J Am Soc Echocardiogr"},{"key":"1075_CR6","doi-asserted-by":"crossref","first-page":"47","DOI":"10.7326\/0003-4819-125-1-199607010-00008","volume":"I25","author":"K Shan","year":"1996","unstructured":"Shan K, Lincoff AM, Young JB. Anthracycline-induced cardiotoxicity. Ann Intern Med. 1996;I25:47\u201358.","journal-title":"Ann Intern Med"},{"key":"1075_CR7","doi-asserted-by":"crossref","first-page":"150","DOI":"10.5603\/KP.a2016.0163","volume":"75","author":"E P\u0142o\u0144ska-Go\u015bciniak","year":"2017","unstructured":"P\u0142o\u0144ska-Go\u015bciniak E, R\u00f3\u017cewicz M, Kasprzak J, et al. Tissue Doppler echocardiography detects subclinical left ventricular dysfunction in patients undergoing chemotherapy for colon cancer: insights from ONCOECHO multicentre study. Kardiol Pol. 2017;75:150\u20136.","journal-title":"Kardiol Pol."},{"key":"1075_CR8","doi-asserted-by":"crossref","first-page":"1487","DOI":"10.6004\/jnccn.2012.0155","volume":"10","author":"AD Zelenetz","year":"2012","unstructured":"Zelenetz AD, Wierda WG, Abramson JS, et al. Non-Hodgkin\u2019s Lymphomas, version 3.2012. J Natl Compr Canc Netw. 2012;10:1487\u201398.","journal-title":"J Natl Compr Canc Netw"},{"key":"1075_CR9","unstructured":"Wojciechowska U, Olasek P, Czauderna K, et al. Cancer in Poland in 2014. Polish National Cancer Registry; Maria Sk\u0142odowska-Curie Institute of Oncology. \n                        http:\/\/onkologia.org.pl\/raporty\/\n                        \n                    . Accessed 19 Oct 2017."},{"key":"1075_CR10","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1093\/annonc\/mdg070","volume":"14","author":"S Limat","year":"2003","unstructured":"Limat S, Demesmay K, Voillat L, et al. Early cardiotoxicity of the CHOP regimen in aggressive non Hodgkin\u2019s lymphoma. Ann Oncol. 2003;14:277\u201381.","journal-title":"Ann Oncol"},{"key":"1075_CR11","doi-asserted-by":"crossref","first-page":"e492","DOI":"10.1016\/S2352-3026(15)00153-2","volume":"2","author":"MV Maraldo","year":"2015","unstructured":"Maraldo MV, Giusti F, Vogelius IR, et al. European Organisation for Research and Treatment of Cancer (EORTC) Lymphoma Group Cardiovascular disease after treatment for Hodgkin\u2019s lymphoma: an analysis of nine collaborative EORTC-LYSA trials. Lancet Haematol. 2015;2:e492\u2013502.","journal-title":"Lancet Haematol."},{"issue":"Supl 5","key":"1075_CR12","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1093\/annonc\/mdq203","volume":"21","author":"H Tilly","year":"2010","unstructured":"Tilly H, Dreyling M. On behalf of the ESMO guidelines working group. Diffuse large B-cell non Hodgkin\u2019s lymphoma: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2010;21(Supl 5):172\u20134.","journal-title":"Ann Oncol."},{"key":"1075_CR13","doi-asserted-by":"crossref","first-page":"e0175544","DOI":"10.1371\/journal.pone.0175544","volume":"12","author":"A Boyd","year":"2017","unstructured":"Boyd A, Stoodley P, Richards D, et al. Anthracyclines induce early changes in left ventricular systolic and diastolic function: a single centre study. PLoS ONE. 2017;12:e0175544.","journal-title":"PLoS ONE"},{"key":"1075_CR14","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1093\/ehjci\/jes139","volume":"14","author":"PW Stoodley","year":"2013","unstructured":"Stoodley PW, Richards DA, Boyd A, et al. Altered left ventricular longitudinal diastolic function correlates with reduced systolic function immediately after anthracycline chemotherapy. Eur Heart J Cardiovasc Imaging. 2013;14:228\u201334.","journal-title":"Eur Heart J Cardiovasc Imaging."},{"key":"1075_CR15","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1016\/j.pcad.2010.06.007","volume":"53","author":"DB Sawyer","year":"2010","unstructured":"Sawyer DB, Peng X, Chen B, et al. Mechanisms of anthracycline cardiac injury: can we identify strategies for cardioprotection? Prog Cardiovasc Dis. 2010;53:105\u201313.","journal-title":"Prog Cardiovasc Dis"},{"key":"1075_CR16","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1016\/j.euje.2005.12.014","volume":"7","author":"RM Lang","year":"2006","unstructured":"Lang RM, Bierig M, Devereux RB, et al. American Society of Echocardiography\u2019s Nomenclature and Standards Committee, Task Force on Chamber Quantification, American College of Cardiology Echocardiography Committee, American Heart Association, European Association of Echocardiography, European Society of Cardiology. Recommendations for chamber quantification. Eur J Echocardiogr. 2006;7:79\u2013108.","journal-title":"Eur J Echocardiogr."},{"key":"1075_CR17","doi-asserted-by":"crossref","first-page":"1981","DOI":"10.1161\/CIRCULATIONAHA.114.013777","volume":"131","author":"D Cardinale","year":"2015","unstructured":"Cardinale D, Colombo A, Bacchiani G, et al. Early detection of anthracycline cardiotoxicity and improvement with heart failure therapy. Circulation. 2015;131:1981\u20138.","journal-title":"Circulation"},{"key":"1075_CR18","doi-asserted-by":"crossref","first-page":"3159","DOI":"10.1200\/JCO.2007.14.1242","volume":"26","author":"DL Hershman","year":"2008","unstructured":"Hershman DL, McBride RB, Eisenberger A, et al. Doxorubicin, cardiac risk factors, and cardiac toxicity in elderly patients with diffuse B-cell non-Hodgkin\u2019s lymphoma. J Clin Oncol. 2008;26:3159\u201365.","journal-title":"J Clin Oncol"},{"key":"1075_CR19","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1016\/j.ejca.2016.02.004","volume":"58","author":"MA Fridrik","year":"2016","unstructured":"Fridrik MA, Jaeger U, Petzer A, et al. Cardiotoxicity with rituximab, cyclophosphamide, non-pegylated liposomal doxorubicin, vincristine and prednisolone\u00a0compared to rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisolone in frontline treatment of patients with diffuse large B-cell lymphoma: a randomised phase-III study from the Austrian Cancer Drug Therapy Working Group (NHL-14). Eur J Cancer. 2016;58:112\u201321.","journal-title":"Eur J Cancer"},{"key":"1075_CR20","doi-asserted-by":"crossref","first-page":"e008350","DOI":"10.1136\/bmjopen-2015-008350","volume":"5","author":"OY Hung","year":"2015","unstructured":"Hung OY, Brown JR, Dai T, et al. Pattern of cardiac surveillance among patients with lymphoma receiving anthracycline-based chemotherapy. BMJ Open. 2015;5:e008350.","journal-title":"BMJ Open"},{"key":"1075_CR21","doi-asserted-by":"crossref","first-page":"791","DOI":"10.1016\/j.jash.2014.08.009","volume":"8","author":"S Szmit","year":"2014","unstructured":"Szmit S, Jurczak W, Zaucha JM, et al. Pre-existing arterial hypertension as a risk factor for early left ventricular systolic dysfunction following (R)-CHOP chemotherapy in patients with lymphoma. J Am Soc Hypertens. 2014;8:791\u20139.","journal-title":"J Am Soc Hypertens."},{"key":"1075_CR22","doi-asserted-by":"publisher","unstructured":"Olivieri J, Perna GP, Bocci C, et al. Modern management of anthracycline-induced cardiotoxicity in lymphoma patients: low occurrence of cardiotoxicity with comprehensive assessment and tailored substitution by nonpegylated liposomal doxorubicin. Oncologist 2017 Mar 8. pii: Theoncologist. 2016-0289. \n                        https:\/\/doi.org\/10.1634\/theoncologist.2016-0289\n                        \n                    .","DOI":"10.1634\/theoncologist.2016-0289"},{"key":"1075_CR23","doi-asserted-by":"crossref","first-page":"300","DOI":"10.1002\/ejhf.8","volume":"16","author":"Y Kang","year":"2014","unstructured":"Kang Y, Xiaoping Xu, Cheng Leilei, et al. Two-dimensional speckle tracking echocardiography combined with high-sensitive cardiac troponin T in early detection and prediction of cardiotoxicity during epirubicine-based chemotherapy. Eur J Heart Fail. 2014;16:300\u20138.","journal-title":"Eur J Heart Fail"},{"key":"1075_CR24","doi-asserted-by":"crossref","first-page":"2129","DOI":"10.1093\/eurheartj\/ehw128","volume":"37","author":"P Ponikowski","year":"2016","unstructured":"Ponikowski P, Voors AA, Anker SD, et al. Authors\/Task Force Members 2016. ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: the Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC) Developed with the special contribution of the Heart Failure Association (HFA) of the ESC. Eur Heart J. 2016;37:2129\u2013200.","journal-title":"Eur Heart J"},{"key":"1075_CR25","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1111\/j.1751-7133.2011.00258.x","volume":"18","author":"A Andres","year":"2012","unstructured":"Andres A, Guglin M. Exaggerated NT-proBNP production in patients with hematologic malignancies: a case series. Congest Heart Fail. 2012;18:333\u20136.","journal-title":"Congest Heart Fail."},{"key":"1075_CR26","first-page":"392","volume":"18","author":"C Charbonnel","year":"2017","unstructured":"Charbonnel C, Convers-Domart R, Rigaudeau S, et al. Assessment of global longitudinal strain at low-dose anthracycline-based chemotherapy, for the prediction of subsequent cardiotoxicity. Eur Heart J Cardiovasc Imaging. 2017;18:392\u2013401.","journal-title":"Eur Heart J Cardiovasc Imaging."}],"container-title":["Medical Oncology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s12032-017-1075-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s12032-017-1075-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s12032-017-1075-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2018,1,4]],"date-time":"2018-01-04T11:46:45Z","timestamp":1515066405000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s12032-017-1075-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,12,22]]},"references-count":26,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2018,1]]}},"alternative-id":["1075"],"URL":"https:\/\/doi.org\/10.1007\/s12032-017-1075-2","relation":{},"ISSN":["1357-0560","1559-131X"],"issn-type":[{"value":"1357-0560","type":"print"},{"value":"1559-131X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,12,22]]},"article-number":"14"}}